A look at the international race to create human eggs and sperm in the lab
By Rob Stein, Regina G. Barber, Berly McCoy,
NPR [cites CGS' Marcy Darnovsky]
| 11. 29. 2023
In which we meet the pioneers of one of the most exciting — and controversial — fields of biomedical research: in vitro gametogenesis, or IVG.
The goal of IVG is to make unlimited supplies of what Hayashi calls "artificial" eggs and sperm from any cell in the human body. That could let anyone — older, infertile, single, gay, trans — have their own genetically related babies. As such, the field opens up a slew of ethical concerns.
But that isn't stopping researchers from pressing forward.
So, this episode NPR science correspondent Rob Stein gives us a glimpse into the global race to create the first artificial human embryos to see how the competition is unfolding.
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...